News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

f-Star, Merck Serono Sign $708 Million Deal for Antibody-Derived Therapeutics


9/7/2011 8:02:05 AM

Antibody engineering firm F-Star could earn up to €492 million as part of a research, license, and commercialization deal with Merck Serono centered on the discovery of antibody-derived therapeutics against inflammatory disease targets. Under terms of the deal, the partners will work together to exploit F-Star’s Modular Antibody Technology for the discovery of monospecific Fc-based targeted biologics (Fcabs) and bispecific IgG-based targeted biologics (mAb² ™) against up to three Merck Serono targets. Merck Serono will have exclusive worldwide development and commercialization rights to resulting products. As well as an initial technology access fee and research-based funding, F-Star will be eligible for license fees, development, regulatory and commercialization milestones, and tiered royalties on product sales.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES